Up­dat­ed: Meta­bol­ic drug de­vel­op­er High­T­ide Ther­a­peu­tics eyes $36M raise with HK IPO

High­T­ide Ther­a­peu­tics, a biotech de­vel­op­ing drugs for meta­bol­ic and di­ges­tive dis­eases in both the US and Chi­na, is seek­ing to raise around $36 mil­lion (HK$278 mil­lion) from an IPO in Hong Kong.

The biotech’s IPO launch comes just un­der a year af­ter it un­veiled a $107 mil­lion Se­ries C. The tar­get range al­so comes well be­low a $200 mil­lion goal when it ini­tial­ly filed for the IPO in June, as re­port­ed by South Chi­na Morn­ing Post.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER